Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients

OBJECTIVE: Sucroferric oxyhydroxide, a novel iron-based phosphate-binder, has been shown to have beneficial effects in lowering serum phosphorus levels and improving renal anemia in clinical studies. Although an effect of this agent on fibroblast growth factor 23 (FGF23) has been reported in an anim...

Descripción completa

Detalles Bibliográficos
Autores principales: Shima, Hisato, Miya, Keiko, Okada, Kazuyoshi, Minakuchi, Jun, Kawashima, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994086/
https://www.ncbi.nlm.nih.gov/pubmed/29884226
http://dx.doi.org/10.1186/s13104-018-3483-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994086/
https://www.ncbi.nlm.nih.gov/pubmed/29884226
http://dx.doi.org/10.1186/s13104-018-3483-6

Ejemplares similares